Daesung Microbiological Labs. Co., Ltd. Overview
Daesung Microbiological Labs is one of Korea's oldest veterinary pharmaceutical manufacturers. It makes about 150 products for cattle, pigs, poultry, bees and companion animals at a single integrated site in Uiwang, Gyeonggi Province. The portfolio covers inactivated and live vaccines, antibiotics, antibacterials, anthelmintics, nutritional and probiotic products, anti-inflammatories, immunostimulants and disinfectants. No single product exceeds roughly 5–10% of sales. The business is predominantly domestic (≈74–80% of revenue). It sells through about 200 dealers, NongHyup channels and Public Procurement Service (PPS) contracts for government vaccination programmes, notably foot-and-mouth disease (FMD) vaccines. Exports go to six countries led by Pakistan, Vietnam and Russia. After four years of stagnant revenue (~KRW 24–26bn) and losses in 2022–2024, it returned to a thin profit in 2025. In March 2026, AI and in-silico consultancy InSilico acquired control. InSilico plans to use DX/AX tools, a bioreactor scale-up and partner-led global distribution to roughly double revenue to KRW 50bn within three years.
What the company does
The company develops, manufactures and sells animal medicines (동물용의약품). Its own disclosures describe about 150 products, grouped as follows:
Preventive vaccines (예방백신): inactivated (killed) and live attenuated vaccines for swine, poultry, cattle and dogs, including FMD vaccines supplied under PPS contracts.
Antibiotics (항생제) and antibacterials (항균제): - Anthelmintics / dewormers (구충제).
Nutritional supplements (영양제): - Antipyretic-analgesic-anti-inflammatory agents (해열진통소염제).
Live-bacteria / enzyme preparations (생균효소제, probiotics): - Immunostimulants (면역증강제).
Disinfectants (소독제): (Source: company description as reported by eToday, 2026-02-15, which draws on the company's periodic report.)
A distinctive feature disclosed by the company is a highly diversified revenue base: the largest individual products each account for only about 5–10% of sales.
Business and revenue model
The company is a product manufacturer. All revenue comes from product sales; it has no subscription, licensing or service revenue. It reports no material royalty income, and the income statement shows no royalty line in FY2025 (ValueLine). Revenue reaches customers through three channels:
-
Domestic dealer network. Direct sales through about 200 animal-medicine dealers (대리점) serving livestock farms. Companion-animal products such as the VLP canine influenza vaccine go through veterinary wholesalers to animal hospitals.
-
Government procurement. Supply contracts won through the Public Procurement Service (조달청), under which preventive vaccines are delivered to government bodies nationwide. FMD vaccine "multiple-supplier contracts" have recurred annually since at least 2023. The press also cites supply to NongHyup (농협) as a domestic channel.
-
Exports. Sales to six countries centred on Pakistan, Vietnam and Russia. The company added channels in Cambodia in 2025 and markets to Uzbekistan, South America, the Middle East and Mongolia.
(Sources: eToday 2026-02-02 and 2026-02-15; Dealsite 2026-03-27.)
Value-chain position
Daesung is a vertically integrated formulator-manufacturer. It carries out antigen production (cell culture, virus inoculation and propagation), harvesting, purification and concentration, inactivation or freeze-drying, filling, sealing and labelling in-house at the Uiwang plant. Its raw materials include cell-culture media, adjuvants, active pharmaceutical ingredients and packaging; raw materials cost ~KRW 9bn a year (ValueLine, FY2025 TTM). Some products rest on technology in-licensed from public research bodies: the VLP canine influenza vaccine and the G2b PED live vaccine both use technology from the Animal and Plant Quarantine Agency (APQA), and Konkuk University transferred live-vaccine technology in 2015.
Customer types and end markets
| End market | Customer type | Products | Channel |
|---|---|---|---|
| Swine | Commercial pig farms | PED vaccines (G2b live and inactivated), bacterial respiratory disease vaccines, antibiotics, FMD vaccines | Dealers, PPS, export |
| Cattle | Beef and dairy farms | FMD vaccines; anthrax/blackleg live mixed vaccine (historic PPS item) | PPS, dealers |
| Poultry | Broiler and layer farms | Poultry vaccines, antibacterials, nutritional products | Dealers, export |
| Apiculture (bees) | Beekeepers | Bee medicines (disclosed as part of the ~150 products) | Dealers |
| Companion animals | Veterinary hospitals | Daesung VLP Flu Dogivac (canine influenza) | Veterinary distributors |
| Government | Municipal and provincial animal-disease agencies | FMD and other national-programme vaccines | PPS multiple-supplier contracts |
Independent characterisation
On the evidence, Daesung is a sub-scale, domestically anchored, broad-line livestock pharmaceutical manufacturer with modern GMP biologics capacity. Its KVGMP vaccine plant was completed in 2021, and the Uiwang plant holds a Eurasian GMP certificate. Revenue has been flat for a decade: KRW 30.8bn in FY2016 versus KRW 26.0bn in FY2025. Gross margins compressed from ~33% (FY2016–2020) to 17–25% (FY2021–2025) as depreciation on the new plant and higher input costs absorbed the gross profit pool. Its competitive identity rests on breadth, a long-standing dealer franchise, eligibility for PPS vaccine programmes, and a few technically differentiated vaccines (VLP and G2b PED). Its main structural weaknesses are low export penetration relative to peers, thin margins, and dependence on volatile government disease-control demand. The 2026 change of control turns the investment case into an execution story about export scale-up and manufacturing productivity under a technology-oriented owner.
Strategy
Stated strategic themes (paraphrased)
The company does not hold investor days. Strategy is drawn from the periodic report summary (via FnGuide/eToday) and the new owner's statements.
-
Product development matched to disease trends. The company says it develops products targeted at currently prevalent diseases and pathogen variants and launches new products steadily (eToday, 2026-02-15).
-
New facility investment to enter advanced markets. The KVGMP investment is framed as the base for regulated export markets (eToday, 2026-02-02).
-
Overseas expansion. Trade fairs, exhibitions and farm visits in Vietnam, Cambodia, South America, the Middle East and Uzbekistan (eToday).
InSilico-era strategy (from March 2026)
| Horizon | Initiative | Detail | Source |
|---|---|---|---|
| Short term | Export scale-up via partners | Shift from country-by-country direct sales to inclusion in global distributors' portfolios. Talks with a feed company covering SE Asia, the Middle East, Africa and the Americas. Management will accept lower margins for faster market entry. | Dealsite 2026-03-27 |
| Short term | Sales organisation reorganisation | Internal restructuring weighted to overseas sales (not finalised) | Dealsite |
| Medium term | DX/AX manufacturing efficiency | Apply InSilico's digital and AI tools to optimise culture conditions, detect process anomalies early and reduce batch variability. The plant is currently accumulating process data. | Dealsite 2026-03-27 |
| Medium term | Suspension culture and bioreactors | Convert adherent culture to suspension; introduce bioreactors by ~2028 for large-scale production | Dealsite |
| Long term | New product development | Use AI-based drug design and in-licensed immunology IP for new animal drugs | Dealsite 2026-03-10 |
| Long term | Global positioning | Aspiration to make the company a global leader within five years | Dealsite 2026-03-27 |
Financial targets (owner-stated, not formal guidance)
| Target | Value | Horizon | Source |
|---|---|---|---|
| Revenue | KRW 50bn (about 1.9x FY2025) | Within 3 years (by ~2029) | Dealsite 2026-03-10/27; BioTimes |
| Operating margin | 10% | Within 3 years | Same |
| Share price | 2x | Within 3 years | Dealsite 2026-03-10 |
| Export revenue | From ~KRW 5bn to KRW 20bn+ | Not specified | Dealsite 2026-03-27 |
ESG or sustainability commitments, cost programmes with quantified targets: none disclosed.
Products & Services
The company does not publish a full catalogue in the sources reviewed. The table below lists every product or product family that could be verified, organised by the single segment and its therapeutic families. Pricing is not disclosed for any product.
Manufacturing formats (Dealsite plant visit, 24 March 2026):
Inactivated vaccines: are made in Building M: pathogen inactivation, adjuvant blending, then fill and seal.
Live vaccines: are made in Building E: lyophilisation, then filling into heat-sterilised vials.
-
The site also has injectables, chemicals and animal-testing buildings.
-
Inactivated and live lines are fully separated, with species-segregated antigen suites.
Note: in 2019 the shares spiked on retail interest in canine dewormers (fenbendazole) as a purported human cancer therapy (eToday headline). This was a market-sentiment episode, not a product launch.
Product Portfolio
| Product / family | Description & key capabilities | Target customer | Launch / latest year | Notes / source |
|---|---|---|---|---|
Daesung VLP Flu Dogivac (대성 VLP 플루 도기백주, "브이엘피플루") | Canine influenza (H3N2) vaccine using a recombinant virus-like particle (VLP) antigen with no viral genetic material. Cell-culture produced, which lowers egg-allergy risk. Licensed for subcutaneous injection; press describes it as Korea's only subcutaneous canine influenza vaccine. National lot-release approved by APQA. | Veterinary hospitals (dogs and cats) | c. 2021 (launch under CEO Cho Hang-won) | Korea's first VLP animal vaccine. Technology transferred from APQA. Sold only to animal hospitals via Woorienpharm, BK Pharm, Busan Veterinary Pharm, VS Pharm, VD House, Kyungsu Pharm and, later, Seoul Veterinary Pharm (DailyVet) |
Daesung PED-Q Live Pigvac (대성 PED-Q Live 피그백주) | G2b-genotype porcine epidemic diarrhoea live vaccine. Korea's first usable by intramuscular injection or orally. Built on an APQA live-attenuated G2b strain. A 10x overdose safety trial in pregnant sows showed no adverse effects. | Pig farms (sows, pre-farrowing) | 2022 | Designated an MAFRA "Excellent R&D Innovative Product" (c. July 2023). Sold through dealers, the national e-procurement mall (나라장터) and the Innovation Market (DailyVet) |
Daesung PED-Q Pigvac (대성 PED-Q 피그백주) | G2b PED inactivated vaccine, recommended in live-live-killed or live-live-killed-killed priming sequences with PED-Q Live | Pig farms | Pre-2022 (exact year not disclosed) | DailyVet |
Porcine bacterial respiratory disease vaccines | Vaccines against bacterial respiratory pathogens in swine; efficacy data presented at FAVA 2024 | Pig farms | — | DailyVet (FAVA 2024 coverage) |
FMD vaccines (구제역백신), 2 types | Supplied to the PPS under annual multiple-supplier contracts: 95,500 vials (2023), 100,000 vials (2024–25) and 115,000 vials (2025–26). The 2025 disclosure states they are self-produced. | Government animal-disease agencies | Recurring annually | DART via Digital Today / Edaily |
Anthrax and blackleg live mixed vaccine (탄저·기종저 생균혼합백신) | Cattle bacterial vaccine; part of an 18-vaccine PPS award | Cattle farms / government | Historic (c. 2011 contract) | eToday |
Other PPS vaccine families | 9 vaccine types (1,048,000 vials) supplied in the 2020 PPS contract | Government | 2020 | eToday |
Antibiotics (항생제) | Livestock antibiotics (specific molecules not disclosed) | Farms via dealers | Ongoing | eToday 2026-02-15 |
Antibacterials (항균제) | Synthetic antibacterials | Farms | Ongoing | eToday |
Anthelmintics (구충제) | Livestock dewormers | Farms | Ongoing | eToday |
Nutritional supplements (영양제) | Vitamins and minerals for livestock | Farms | Ongoing | eToday |
Antipyretic-analgesic-anti-inflammatories (해열진통소염제) | Supportive therapeutics | Farms / veterinarians | Ongoing | eToday |
Live-bacteria / enzyme products (생균효소제) | Probiotic and enzyme feed-administered products | Farms | Ongoing | eToday |
Immunostimulants (면역증강제) | Immune-enhancing products | Farms | Ongoing | eToday |
Disinfectants (소독제) | Farm biosecurity disinfectants; demand rises during ASF, FMD and HPAI outbreaks | Farms / government | Ongoing | eToday |
Bee medicines | Apiculture medicines produced at Uiwang alongside cattle, pig and poultry products | Beekeepers | Ongoing | Dealsite 2026-03-27 |
“—” = not publicly disclosed.
Financial Narrative
All figures are from separate (non-consolidated) IFRS statements filed with DART, as aggregated by ETF Shopping, Butler and ValueLine. Units are KRW 100M unless stated.
Income statement
Sources: revenue, cost of sales, gross profit, operating income and EPS from DART via ETF Shopping and Butler. FY2025 SG&A, EBITDA, interest, pre-tax and tax from ValueLine (FY2025 annualised column). Net income from Butler. Diluted EPS is not separately disclosed in sources reviewed; no convertible or warrant instruments were identified.
Revenue CAGR. FY2021–FY2025: +2.0% p.a. (KRW 240 → 260 x100M). FY2016–FY2025: -1.9% p.a. (KRW 308 → 260 x100M). Both computed.
Quarterly trajectory (chartable):
Source: DART periodic reports via ETF Shopping (filed 2024-05-14 through 2026-08-14).
Commentary — income statement.
FY2021–FY2022: margin compression after the KVGMP investment: Revenue was stable at KRW 24–26bn, but gross margin collapsed from the ~33% achieved in FY2016–FY2020 to 23.9% in FY2021 and 18.8% in FY2022. The timing matches the 2021 commissioning of the KVGMP vaccine facility. Depreciation stepped up, and machinery on the balance sheet rose sharply again in FY2024 (KRW 87.9 → 118.1 x100M). Fixed overhead was spread over a revenue base that did not grow. FY2022 net income of KRW 1.7bn against an operating loss implies non-operating gains; their nature is not disclosed in the sources reviewed.
FY2023–FY2024: the trough: Revenue fell 6.9% in FY2024 to KRW 23.8bn. Management attributes this to weak exports in 2024 (eToday, 2026-02-15). The operating loss deepened to KRW -1.6bn and the net loss to KRW -1.8bn, the worst result of the decade. Q2 and Q3 FY2024 alone lost KRW 1.9bn at the operating line.
FY2025: inflection: Revenue grew 9.2% to KRW 26.0bn and gross margin recovered to 24.8%, so operating profit turned positive at KRW 0.71bn. Sujuradar attributes the profit recovery mainly to better profitability on existing products rather than to new launches. The company points to new export channels such as Cambodia (eToday). Growth was concentrated in Q2–Q3 FY2025 (+19.3% and +23.5% YoY). Net income was helped by a KRW 0.26bn tax benefit, because pre-tax income was only KRW 0.33bn after ~KRW 0.6bn of interest expense.
FY2026 year to date: relapse: H1 FY2026 revenue fell to KRW 11.1bn (-6.7% YoY), and both Q1 and Q2 posted operating losses of KRW 0.5bn each. On a trailing-twelve-month basis to June 2026, revenue is KRW 25.19bn, operating income KRW -0.66bn, EBITDA KRW 2.66bn and net income KRW 0.35bn (ValueLine TTM). The relapse coincides with the ownership transition and with weak drawdown on the FMD contract.
Balance sheet
Source: ValueLine balance sheet (DART separate statements). Net debt and working capital are analyst-computed. At Q1 FY2026: total assets KRW 573.4, borrowings KRW 195.4 (14.8 ST + 45.6 current LT + 135.0 LT) and equity KRW 349.2 x100M.
Commentary — balance sheet.
Asset-heavy, PP&E-dominated balance sheet: PP&E of KRW 29.6bn is 51% of total assets. It comprises buildings of KRW 15.0bn, machinery of KRW 10.7bn and land at a historic KRW 3.0bn book value. The company holds no goodwill, and intangibles are minimal and falling. Capitalised development costs shrank from KRW 0.51bn (FY2022) to KRW 0.07bn (FY2025).
Leverage is moderate on equity but heavy relative to earnings. Borrowings of ~KRW 19.6bn equal 55% of equity but about six times FY2025 EBITDA on a gross basis (3.1x net). In FY2025, KRW 4.6bn of long-term debt moved to current, creating a 2026 refinancing requirement. This is the largest near-term balance-sheet monitorable. The cash-flow data show the company refinanced roughly KRW 15.5bn of long-term debt in mid-2024, which explains the FY2024 swing from current to long-term.
Liquidity buffer: Cash plus short-term deposits of KRW 9.4bn (FY2025) cover the current portion of debt about twice over. The buffer has shrunk from KRW 12.9bn at FY2022.
Working-capital intensity is extreme: inventories are ~41% of revenue.
Cash flow
Sources: FY2025 OCF and capex from ValueLine cash-flow data (DART). Dividends paid are analyst-derived as the prior-year DPS times ~3.8M shares, consistent with the KRW 2.8 x100M dividend outflow ValueLine shows. ETF Shopping (DART) records no buybacks. The data provider computes FY2025 "free cash flow" at KRW 3.2 x100M using a broader outflow definition; the analyst figure above uses PP&E capex only. On a TTM basis to June 2026: OCF KRW 9.7 and PP&E capex KRW 3.5 x100M.
Commentary — cash flow. FY2025 OCF of KRW 1.41bn was more than twice net income because ~KRW 2.5bn of non-cash D&A was added back. About KRW 2.0bn of working-capital build partly offset this, mainly a KRW 1.4bn rise in receivables, consistent with H2 FY2025 PPS deliveries. Capex is running at maintenance level (KRW 0.35bn a year) despite the stated plan to convert from adherent to suspension culture and install bioreactors. That programme is not yet visible in cash flows, and it will need either a capex step-up or a contribution from the parent. Dividends (~KRW 0.29bn a year) have been sustained through loss years, which suggests a policy of a stable payout regardless of earnings.
Ratios
All ratios are analyst-computed from the tables above. The 22% tax rate in ROIC is an analyst assumption approximating the Korean statutory rate. ETF Shopping reports FY2025 ROE of 1.7% and ROA of 1.0%, consistent with these figures.
Commentary — ratios. Returns are well below any reasonable cost of capital: ROIC peaked at about 1% in the best recent year. Interest coverage of 1.2x in FY2025 leaves almost no cushion, and in H1 FY2026 operating income again fell short of interest expense. The cash conversion cycle of ~230–250 days is structural for a broad-line vaccine maker. Biologics require long batch lead times, release testing and seasonal stock-building for PPS programmes, so roughly KRW 10.5bn of inventory sits against KRW 19.6bn of annual cost of sales. Work-in-process rose from KRW 4.8bn (FY2024) to KRW 6.6bn (Q1 FY2026), which may be stock-building ahead of FMD and export demand that did not fully materialise. Productivity gains from DX/AX would show up first in DIO and gross margin; these are the most direct tests of the new owner's thesis.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment (KRW) and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Veterinary pharmaceuticals – Revenue (KRW 100M) | 256 | 238 | 260 |
Veterinary pharmaceuticals – Operating income (KRW 100M) | -7 | -16 | 7 |
Veterinary pharmaceuticals – Operating margin (%) | -2.7 | -6.5 | 2.7 |
Veterinary pharmaceuticals – Revenue growth YoY (%) | 0.2 | -6.9 | 9.2 |
Veterinary pharmaceuticals – Share of total revenue (%) | 100 | 100 | 100 |
Product Families
| Product family (Q1 FY2026) | Value (KRW 100M) | Share of product revenue (%) |
|---|---|---|
"Other products" (기타 제품군; the largest category disclosed) | 33.6 | 66.1 |
Total product revenue, Q1 FY2026 | 50.82 | 100 |
Income Statement (KRW) and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW 100M) | 240 | 255 | 256 | 238 | 260 |
Cost of sales (KRW 100M) | 183 | 207 | 207 | 198 | 196 |
Gross profit (KRW 100M) | 57 | 48 | 48 | 41 | 64 |
SG&A (KRW 100M) | — | — | — | — | 57.2 |
Operating income (KRW 100M) | 3 | -3 | -7 | -16 | 7 |
EBITDA (KRW 100M) | — | — | — | — | 32.6 |
Interest expense (KRW 100M) | — | — | — | — | 6.0 |
Pre-tax income (KRW 100M) | — | — | — | — | 3.3 |
Income tax (KRW 100M; negative = benefit) | — | — | — | — | -2.6 |
Net income (KRW 100M) | 9 | 17 | -7 | -18 | 6 |
EPS basic (KRW) | 227 | 448 | -179 | -466 | 157 |
Dividend per share (KRW) | 75 | 75 | 75 | 75 | 75 |
Gross margin (%) | 23.9 | 18.8 | 19.0 | 17.0 | 24.8 |
Operating margin (%) | 1.4 | -1.3 | -2.7 | -6.5 | 2.7 |
EBITDA margin (%) | — | — | — | — | 12.5 |
Net margin (%) | 3.8 | 6.7 | -2.7 | -7.4 | 2.3 |
Income Statement (KRW)
| Metric | Q1FY2024 | Q2FY2024 | Q3FY2024 | Q4FY2024 | Q1FY2025 | Q2FY2025 | Q3FY2025 | Q4FY2025 | Q1FY2026 | Q2FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW 100M) | 56 | 56 | 58 | 68 | 52 | 67 | 72 | 69 | 51 | 60 |
Operating income (KRW 100M) | -3 | -10 | -9 | 7 | -3 | 7 | 6 | -3 | -5 | -5 |
Balance Sheet (KRW) and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW 100M) | 651.0 | 642.9 | 583.7 | 579.7 |
Current assets (KRW 100M) | 286.9 | 287.1 | 236.4 | 252.3 |
Cash & cash equivalents (KRW 100M) | 38.5 | 43.6 | 36.3 | 34.4 |
Short-term financial instruments (KRW 100M) | 90.0 | 73.6 | 54.2 | 59.4 |
Trade receivables (KRW 100M) | 30.4 | 41.3 | 37.7 | 50.2 |
Inventories (KRW 100M) | 116.4 | 124.9 | 104.8 | 105.5 |
Property, plant & equipment (KRW 100M) | 331.3 | 319.3 | 314.0 | 296.0 |
Goodwill (KRW 100M) | 0 | 0 | 0 | 0 |
Intangible assets (KRW 100M) | 8.7 | 6.8 | 5.4 | 4.2 |
Current liabilities (KRW 100M) | 106.1 | 103.9 | 45.3 | 85.3 |
Short-term borrowings (KRW 100M) | 20.0 | 53.1 | 10.0 | 15.0 |
Current portion of long-term borrowings (KRW 100M) | 43.5 | 21.2 | 7.5 | 46.2 |
Long-term borrowings (KRW 100M) | 155.0 | 163.7 | 181.2 | 135.0 |
Total borrowings (KRW 100M) | 218.5 | 238.0 | 198.7 | 196.2 |
Net debt (borrowings less cash and ST financial instruments; KRW 100M) | 90.0 | 120.8 | 108.2 | 102.4 |
Total liabilities (KRW 100M) | 262.7 | 269.4 | 232.3 | 225.5 |
Shareholders' equity (KRW 100M) | 388.3 | 373.4 | 351.4 | 354.2 |
Working capital (KRW 100M) | 180.8 | 183.2 | 191.1 | 167.0 |
Book value per share (KRW) | 10,220 | 9,829 | 9,250 | 9,321 |
Cash Flow (KRW)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW 100M) | — | — | — | — | 14.1 |
Capital expenditure, PP&E (KRW 100M) | — | — | — | — | 3.5 |
Free cash flow, OCF less PP&E capex (KRW 100M) | — | — | — | — | 10.6 |
Dividends paid (KRW 100M) | 3.2 | 2.9 | 2.9 | 2.9 | 2.9 |
Share buybacks (KRW 100M) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on year-end equity (%) | 4.4 | -1.9 | -5.1 | 1.7 |
ROA on year-end assets (%) | 2.6 | -1.1 | -3.1 | 1.0 |
ROIC, NOPAT at 22% tax / (equity + net debt) (%) | -0.5 | -1.1 | -2.7 | 1.2 |
Current ratio (x) | 2.70 | 2.76 | 5.22 | 2.96 |
Debt-to-equity (x) | 0.56 | 0.64 | 0.57 | 0.55 |
Net debt / EBITDA (x) | — | — | — | 3.1 |
Interest coverage, operating income / interest expense (x) | — | — | — | 1.2 |
Asset turnover, revenue / year-end assets (x) | 0.39 | 0.40 | 0.41 | 0.45 |
Days sales outstanding (days) | 44 | 59 | 58 | 71 |
Days inventory outstanding (days) | 205 | 220 | 193 | 197 |
Days payables outstanding (days) | 17 | 27 | 24 | 21 |
Cash conversion cycle (days) | 232 | 252 | 227 | 246 |
Region (KRW 100M) Overview
| Region (KRW 100M) | 9M FY2025 | Share (%) |
|---|---|---|
Domestic (Korea) | 141 | 74 |
Export | 50 | 26 |
Total | 191 | 100 |
Region (KRW 100M) Overview (FY2025)
| Region (KRW 100M) | FY2025 |
|---|---|
Export (approximate, per CEO) | 50 |
Domestic (derived: total less export) | 210 |
Valuation Multiples (KRW) and Valuation Multiples (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 10,300 | 10,950 | 9,090 | 7,300 |
Year-end market capitalisation (KRW 100M) | 391.4 | 416.1 | 345.4 | 277.4 |
Year-end P/B (x) | 1.01 | 1.11 | 0.98 | 0.78 |
Share Price & Returns
| Reference point | Price (KRW) | Date | Source |
|---|---|---|---|
Intraday high during the FMD emergency | ~17,130 | 2023-05-16 | eToday |
ASF spike (intraday) | 8,810 | 2026-02-02 | eToday |
Limit-up on control-deal announcement | 8,120 | 2026-03-10 | JoongAng Economy News |
Deal price paid by InSilico | 11,000 | 2026-03-09 | DART |
Parent's market purchases (average, final tranche) | 6,606 | June 2026 | Greened |
Latest close | 5,750 | 2026-10-20 | ETF Shopping |
52-week high / low | 9,880 / 5,590 | to 2026-10-20 | ETF Shopping |
Valuation Multiples
| Multiple | Daesung | Choong Ang Vaccine | Eagle Vet | Woogene B&G | Komipharm |
|---|---|---|---|---|---|
P/E on FY2025 EPS (x) | 36.6 | 10.8 | 7.1 | Negative | Negative |
P/E on TTM to Jun-2026 (x) | 62.3 | — | — | — | — |
P/B (x) | 0.61 | 0.80 | 0.71 | 0.58 | 10.22 |
EV/EBITDA FY2025 (x) | 9.8 | — | — | — | — |
EV/EBITDA TTM Jun-2026 (x) | 12.1 | — | — | — | — |
EV/Sales FY2025 (x) | 1.23 | — | — | — | — |
Dividend yield (%) | 1.30 | 2.15 | 2.61 | 0 | 0 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (KRW) | 75 | 75 | 75 | 75 | 75 |
Payout ratio (%) | 33 | 17 | — | — | 48 |
Debt Maturity Profile
| Maturity bucket (KRW 100M) | FY2025 |
|---|---|
Short-term borrowings (≤1 year) | 15.0 |
Current portion of long-term borrowings (≤1 year) | 46.2 |
Long-term borrowings (>1 year) | 135.0 |
Total borrowings | 196.2 |
Analyst Conclusions
Guidance and expectations
Formal guidance: none issued.
Owner targets: revenue of KRW 50bn and a 10% operating margin within three years; share price to double; exports above KRW 20bn (Dealsite, March 2026).
Consensus: none (no coverage).
Run-rate reality check: H1 FY2026 revenue was KRW 11.1bn (-6.7% YoY) with a KRW 1.0bn operating loss. TTM revenue is KRW 25.2bn and TTM operating income KRW -0.66bn (ValueLine). Meeting the 3-year target from here implies roughly 25–30% revenue CAGR over FY2026–FY2029.
Bull case
-
Export inflection via partner distribution. If the feed-company partnership is signed and products are registered, management's arithmetic implies a step-up. Moving exports from ~KRW 5bn to KRW 20bn would take revenue above KRW 40bn. Incremental volume through a plant with spare capacity would carry high incremental margins, given the fixed-cost structure (FY2025 gross margin rose 7.8pp on 9.2% revenue growth).
-
Asset-backed downside. At 0.61x book (equity KRW 35.4bn vs market cap KRW 21.9bn), with a KVGMP plant, land carried at historic cost, a stable dividend and a parent that paid KRW 11,000/share, there is a valuation floor and a credible incentive for the parent to support the share price.
-
Disease-cycle optionality. ASF (5th national case in Feb 2026), PED (recurring in 2026) and FMD (an emergency SAT1 procurement by a peer in July 2026) keep vaccine and disinfectant demand structurally elevated. Daesung has PPS eligibility and differentiated PED and VLP products positioned to capture spikes, as the 2023 and 2026 share-price reactions show.
Bear case
-
Earnings relapse and weak debt cover. Two consecutive quarterly operating losses in FY2026 and TTM operating income below interest expense (~KRW 0.6bn a year) show the FY2025 recovery was not durable. A KRW 4.6bn current debt maturity adds refinancing pressure.
-
Government-demand dependence. Only 41% of the 2025–26 FMD ceiling was executed, and no 2026–27 award had been disclosed by 20 October 2026. The largest domestic revenue line is therefore uncertain, and peers compete for the same contracts.
-
Governance and execution uncertainty. The new owner is an IT/AI consultancy with no veterinary-manufacturing record. Its acquisition financing is undisclosed, the merger option creates minority-dilution risk, and the stated targets are aggressive relative to a decade of flat revenue.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable | What to watch |
|---|---|---|
| ~Mid-Nov 2026 | Q3 FY2026 report | Return to operating profit; export revenue; inventory and WIP |
| Q4 2026 | 2026–27 PPS FMD vaccine contract | Award size vs KRW 3.3–4.0bn history; drawdown visibility |
| H2 2026 – 2027 | Global feed-company distribution partnership | Signing, territories, product registrations |
| Nov 2026 | KAHPA pavilion at EuroTier 2026 (Germany) | Any Daesung participation or EU-adjacent registrations |
| 2026–2027 | Refinancing of ~KRW 4.6bn of current long-term debt | Terms; any parent guarantee or funding |
| 2026–2028 | Suspension-culture conversion and bioreactor capex | Capex disclosures; gross-margin trend; DIO |
| Feb–Mar 2027 | FY2026 dividend decision and AGM | Whether KRW 75 DPS is maintained; board changes |
| Ongoing | ASF / FMD / HPAI / PED outbreaks | Emergency procurement; disinfectant and vaccine demand |
| Ongoing | Parent actions (further buying, merger, related-party contracts) | DART disclosures by InSilico |
Analyst verdict
Daesung Microbiological Labs is a 60-year-old Korean veterinary-medicine manufacturer at an inflection point it has not yet earned. The franchise is real: about 150 products, a dealer network of roughly 200, recurring government vaccine eligibility, a KVGMP biologics plant with Eurasian GMP, and two technically differentiated vaccines (VLP canine flu and G2b PED live). The financial record does not yet support the strategic narrative. Revenue in FY2025 (KRW 26.0bn) remained below FY2016. FY2025 was the only profitable year at the operating line since FY2021, and the operating margin was just 2.7%. The first half of FY2026 slipped back into losses as government FMD drawdowns fell to 41% of contract ceiling.
The March 2026 sale of the founding family's 38.6% stake to InSilico, at a 74% premium, reframes the case. The new owner has set aggressive goals (KRW 50bn revenue, 10% OPM and a doubled share price within three years) and a coherent playbook: partner-led exports, data-driven process optimisation, and a bioreactor scale-up. The plan's logic is sound because the plant has operating leverage and exports are under-penetrated relative to peers such as Choong Ang Vaccine. Execution capability in animal-health manufacturing is unproven, the financing and related-party arrangements are opaque, and interest coverage near 1x leaves little room for delay.
At 0.61x book and ~10–12x EV/EBITDA, the market is pricing a low-return utility with an asset floor, not the owner's targets. The shares now trade near half the parent's purchase price. The balance of evidence supports a "Watch / speculative turnaround" stance. Hard evidence would warrant reassessment: a signed distribution partnership with registrations under way, a sustained return to quarterly operating profit, and a 2026–27 FMD award of historical size. Until then, downside is cushioned by assets but upside is contingent on events not yet visible in the numbers.
Source list (primary aggregators of DART data and press)
-
DART filings as aggregated by ETF Shopping: etfshopping.com/stock/036480, /earnings and /company (retrieved 2026-10-20)
-
Butler: butler.works/ko/companies/00177320, plus peer pages 00415327 (CAVAC), 00145473 (Eagle Vet), 00103547 (Woogene B&G) and 00187415 (Komipharm)
-
ValueLine/DataHero: valueline.co.kr/finance/income, balancesheet and cashflow pages for 036480
-
Sujuradar: sujuradar.com/company/00177320
-
Chickstock: chickstockfi.com/disclosures/20260930900583
-
Dealsite: articles 158132 (2026-03-10), 158976 (2026-03-26), 159102 and 159151 (2026-03-27)
-
eToday: 2026-02-02 (ASF), 2026-02-15 (KVGMP/exports), 2023-05-16 (FMD), 2020-01-02 (PPS contract)
-
Digital Today AI disclosure, 2025-10-15; Nate/Digital Today, 2026-03-13
-
Edaily: 2024-08-21 and 2025-10-15 contract disclosures; 2026-07-08 (CAVAC SAT1 FMD contract)
-
Chuksan News (2026-03); BioTimes (2026-03-10); JoongAng Economy News (2026-03-10); Greened (June 2026)
-
DailyVet: PED-Q Live and VLP Flu Dogivac product notices; KAHPA trade missions; KAHPA market data (2020, 2024, 2025, 2026)
-
Herald Economy (2015 PPS contract); Daehak Journal (2015 Konkuk technology transfer)
-
Financial News (2007 CAVAC market share); Zoetis FY2025 results summary (Feb 2026)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background / education | Compensation | Source |
|---|---|---|---|---|---|
Choi Seung-hoon (최승훈) | CEO (대표이사); also CEO of InSilico | Since March 2026 | MS and PhD in biophysical chemistry, KAIST. Previously researched molecular modelling and AI-based materials design at Samsung SDI. Worked about two years at a drug-development venture. Founded and leads InSilico, which provides AI and computer-simulation drug-discovery consulting and DX-based quality-management solutions to Samsung Biologics, Hanmi Pharm, Dong-A and others. Holds about 56% of InSilico with related parties. | Not individually disclosed (below the KRW 500M threshold) | Dealsite 2026-03-10, 03-26, 03-27 |
Lee Jae-hak (이재학) | Senior Managing Director (전무); leads plant operations and manufacturing | — | Led the March 2026 plant tour; responsible for the suspension-culture and bioreactor roadmap and the Eurasian GMP certification | — | Dealsite 2026-03-27 |
Lee Hoon-gu (이훈구) | Former CEO; former 6.58% shareholder (relative of Lee Dong-kyu) | CEO c. 2023 – March 2026 (approximate) | Sold 250,000 shares to InSilico in 2026 | — | DailyVet; Nate/Digital Today (DART) |
Cho Hang-won (조항원) | Former CEO | c. 2021–2022 (approximate) | Oversaw the VLP Flu Dogivac and PED-Q Live launches | — | DailyVet |
Lee Dong-kyu (이동규) | Former largest shareholder (32.02%) | Until March 2026 | Sold 1,216,740 shares to InSilico. Board role not confirmed in sources reviewed. | — | DART via ETF Shopping; Nate |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Shares | Stake (%) | As of | Source |
|---|---|---|---|---|
InSilico Co., Ltd. | 1,504,640 | 39.60 | June 2026 | Greened (KIND filing) |
Minority shareholders (5,775 holders) | — | 53.1 | 2025-12-31 | DART via ETF Shopping |
Other / unidentified | — | ~7.3 | Derived | Analyst |
Former: Lee Dong-kyu | 1,216,740 | 32.02 | 2025-12-31 (sold March 2026) | DART |
Former: Lee Hoon-gu | 250,000 | 6.58 | 2025-12-31 (sold March 2026) | DART |
Competitive Landscape
Peer Comparison FY2025
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Daesung Microbiological – Revenue (KRW 100M) | 240 | 255 | 256 | 238 | 260 |
Choong Ang Vaccine – Revenue (KRW 100M) | 409 | 393 | 419 | 456 | 491 |
Eagle Vet – Revenue (KRW 100M) | 404 | 435 | 428 | 417 | 433 |
Woogene B&G – Revenue (KRW 100M) | 393 | 437 | 579 | 557 | 548 |
Komipharm – Revenue (KRW 100M) | 358 | 398 | 426 | 588 | 525 |
Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
Daesung Microbiological – Operating income (KRW 100M) | 3 | -3 | -7 | -16 | 7 |
Choong Ang Vaccine – Operating income (KRW 100M) | 45 | 43 | 70 | 58 | 65 |
Eagle Vet – Operating income (KRW 100M) | 42 | 36 | 33 | 35 | 43 |
Woogene B&G – Operating income (KRW 100M) | 3 | 12 | 7 | 3 | 3 |
Komipharm – Operating income (KRW 100M) | -53 | -38 | -63 | 62 | 20 |
Peer Comparison FY2025 — Revenue FY2025
| Metric | Daesung | Choong Ang Vaccine | Eagle Vet | Woogene B&G |
|---|---|---|---|---|
Revenue FY2025 (KRW 100M) | 260 | 491 | 433 | 548 |
Revenue growth FY2025 (%) | 9.2 | 7.6 | 3.9 | -1.6 |
Operating margin FY2025 (%) | 2.7 | 13.2 | 9.9 | 0.5 |
Net margin FY2025 (%) | 2.3 | 12.6 | 9.0 | -6.6 |
Market cap (KRW 100M) | 219 | 862 | 388 | 186 |
P/B (x) | 0.61 | 0.80 | 0.71 | 0.58 |



